Top-line data now anticipated mid-2025 The BOLSTER trial is a Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating certepetide in combination with standard-of-care (gemcitabine/cisplatin/durvalumab) versus standard-of-care alone in patients with first-line CCA in the United States. The rapid enrollment of this cohort underscores the urgent need for new treatment options for patients with CCA, a difficult-to-treat solid tumor with a poor prognosis. Based on this rapid enrollme ...

Group 1 - Proactive specializes in providing fast, accessible, and informative business and finance news content to a global investment audience [1][2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] - Proactive's news team operates from key finance and investing hubs worldwide, including London, New York, Toronto, Vancouver, Sydney, and Perth [4] Group 2 - The content produced by Proactive includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [5] - Proactive employs technology to enhance workflows, utilizing automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [6][7]

BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announces promising preclinical results for its investigational candidate, certepetide (formerly LSTA1). The data, presented in a poster by Dr. Dan G. Duda of Massachusetts General Hospital at the 2024 Cholangiocarcinoma Foundation Annual ...

BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announces promising preclinical results for its investigational candidate, certepetide (formerly LSTA1). The data, presented in a poster by Dr. Dan G. Duda of Massachusetts General Hospital at the 2024 Cholangiocarcinoma Foundation Annual ...

Proactive: You've completed patient enrollment for the pancreatic cancer cohorts in your phase 1b/2a clinical trial. That's another milestone for the trial. This trial, conducted in conjunction with a university cancer center, allows us to see pre- and post-treatment biopsies of the tumors. This provides us with physiological and quantitative information regarding cytotoxic T cell infiltration of the tumors. It corroborates in humans what we've previously seen in animals and anecdotally in other studies – t ...

Contact: Lisata Therapeutics, Inc. John Menditto Vice President, Investor Relations and Corporate Communications Phone: 908-842-0084 Email: jmenditto@lisata.com Media: ICR Westwicke Elizabeth Coleman Senior Associate Phone: 203-682-4783 Email: elizabeth.coleman@westwicke.com Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, ...

BASKING RIDGE, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced today the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial. This investigatorinitiated trial, led by Dr. Anup Kasi at The University of Kansas ("KU") Cancer Center, is eval ...

Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech companies over the past three years as they seek recognition in a market that has performed 'a 180' turn since the peak of Covid vaccines interest in the sector in 2021. Risk capital has been sidelined during this politically and economically volatile period, not just in life sciences, but across microcap markets internationally. Still, for those would-be in ...

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June: BIO International Convention (June 3-6, 2024) Format: In-person Location: San Diego, California Presentation Date: Monday, June 3, 2024 Presentation Time: 2:15 p.m ...

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June: BIO International Convention (June 3-6, 2024) Format: In-person Location: San Diego, California Presentation Date: Monday, June 3, 2024 Presentation Time: 2:15 p.m ...